Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript November 14, 2023 10:00 AM ET

Company Participants

Kim Golodetz - Investor Relations, LHA

Corinne Le Goff - President & Chief Executive Officer

Jeffrey Church - Chief Financial Officer

Khursheed Anwer - Chief Science Officer

Conference Call Participants

Emily Bodnar - HC Wainwright

James Molloy - Alliance Global Partners

Kemp Dolliver - Brooklyn Capital Markets

David Bautz - Zacks Small-Cap Research

Operator

Good morning. My name is Alan, and I will be your operator today. At this time I would like to welcome you to Imunon's Third Quarter 2023 Financial Results Conference Call. [Operator Instructions]

I would like now to turn the call over to Kim Golodetz. Please go ahead.

Kim Golodetz

Thank you and good morning everyone. This is Kim Golodetz with LHA. Welcome to Imunon's 2023 third quarter financial results and business update conference call. During today's call, management will be making forward-looking statements regarding Imunon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expect, anticipates, believes or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements.

I also caution that the content of this conference call is accurate only as of the date of the live broadcast, November 14, 2023. Imunon undertakes no obligation to revise or update comments made during this call except as required by law.

With that said, I would like to turn the call over to Dr. Corinne Le Goff, Imunon's President and Chief Executive Officer. Corinne?

Corinne Le Goff

Thank you, Kim, and good morning, everyone. Joining me today is Jeffrey Church, our Chief Financial Officer. In addition, Dr. Khursheed Anwer, our Chief Science Officer, will be available during the Q&A session at the end of our prepared remarks.

Imunon's growth and development is dependent on four pillars. Last quarter, I spent the bulk of our time on the development of our PlaCCine prophylactic vaccines modality as an out-licensing and partnership opportunity. While I will certainly update you on this modality and we did have some interesting developments, first, I'd like to highlight IMNN-001 or DNA-based Interleukin 12 immunotherapy for the localized first line treatment of advanced ovarian cancer in combination with a standard-of-care chemotherapy, and it's currently in Phase II clinical development. Recall that in September 2022, we reached full enrollment of 110 patients and this year, in September 2023, we reported an additional set of interim, more mature data, showing promising progression free survival and overall survival data. In the intent-to-treat population, we demonstrated a delay in disease progression in the treatment arm of approximately 33% or more than three months benefit and preliminary overall survival data followed a similar trend showing an approximate nine month improvement in the treatment arm over the control arm. [Indiscernible] ratio of 0.78 approaches the critical defined value of 0.75 set at an 80% confidence interval for the ITT population.